Cemiplimab monotherapy could be a new treatment option for first line advanced NSCLC patients

Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients

Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies

Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC

Choosing 1st line TKI Wisely in patients with CML

Common Sense Oncology in head & neck cancers

Head & Neck - BMC Data

Amivantamab-lazertinib continue to show benefit as a first-line standard-of-care for EGFR-mutated advanced NSCLC

TROP2 expression measured by QCS is a promising predictor of clinical outcomes in patients with mNSCLC

How to write a paper

Ethical issues in scientific publishing and navigating them

Choosing the right patients for transplant